The Right Reforms, the Wrong Narrative: Why the Medical Cannabis Debate Is Missing Half the Picture

Medical
Read More

Green Shoots: Spring 2026 Brings Integration, Recovery, and New Supply Chains to Global Cannabis

Markets & Stocks
Read More

Five Years, 74 Patients: Ireland Moves Forward With Review of Its Failing Medical Cannabis Programme

Medical
Read More

CBD Enters US Healthcare Through Medicare Pilot, But Coverage Remains Limited

CBD & Hemp
Read More

Recent Searches

    Popular Searches

    • Glass Pharms
    • medical
    • Medical Cannabis
    • Kanabo Calls in Administrators
    • Article
    • Cannabis Health Symposium
    • antiflamx near me abbotsford bc
    • teaching feeling scene
    • for driving licence test
    • LEADER AM

    Recent Searches

      Popular Searches

      • Glass Pharms
      • medical
      • Medical Cannabis
      • Kanabo Calls in Administrators
      • Article
      • Cannabis Health Symposium
      • antiflamx near me abbotsford bc
      • teaching feeling scene
      • for driving licence test
      • LEADER AM
      Policy & Regulation, Videos, Your #1 Podcast on Cannabis News

      Lucas McCann, Co-Founder and Chief Scientific Officer, CannDelta

      By
      BofC

      On this episode – BofC Live features conversation with Lucas McCann, co-founder and Chief Scientific Officer of CannDelta. CannDelta Inc. is a cannabis regulatory consulting company based out of Toronto, Canada.

      Listen to this episode as a podcast.

      BofC

      Other featured articles

      The Right Reforms, the Wrong Narrative: Why the Medical Cannabis Debate Is Missing Half the Picture

      By

      Five Years, 74 Patients: Ireland Moves Forward With Review of Its Failing Medical Cannabis Programme

      By

      CBD Enters US Healthcare Through Medicare Pilot, But Coverage Remains Limited

      By

      Züri Can Extended By Two Years As Results Point To Black Market Deterrence

      By

      Oliver’s Law: The Campaign That Could Reshape UK Cannabis Prescribing

      By

      Other featured Policy & Regulation articles

      Five Years, 74 Patients: Ireland Moves Forward With Review of Its Failing Medical Cannabis Programme

      By

      CBD Enters US Healthcare Through Medicare Pilot, But Coverage Remains Limited

      By

      Züri Can Extended By Two Years As Results Point To Black Market Deterrence

      By

      Oliver’s Law: The Campaign That Could Reshape UK Cannabis Prescribing

      By

      Has UK’s ‘Brexit Reset’ Derailed 5-Year CBD Approval Battle?

      By

      Share Article

      Related news

      Medical
      The Right Reforms, the Wrong Narrative: Why the Medical Cannabis Debate Is Missing Half the Picture

      By

      Medical
      Five Years, 74 Patients: Ireland Moves Forward With Review of Its Failing Medical Cannabis Programme

      By

      CBD & Hemp
      CBD Enters US Healthcare Through Medicare Pilot, But Coverage Remains Limited

      By

      Adult-Use
      Züri Can Extended By Two Years As Results Point To Black Market Deterrence

      By

      Medical
      Oliver’s Law: The Campaign That Could Reshape UK Cannabis Prescribing

      By

      CBD & Hemp
      Has UK’s ‘Brexit Reset’ Derailed 5-Year CBD Approval Battle?

      By

      Policy & Regulation
      ‘How Does the DEA Plan to Reschedule Without a Judge?’ – Lawmaker Demands Answers on Cannabis Rescheduling Chaos

      By

      News
      White House to Meet With Cannabis Industry On Overdue CBD Enforcement Policy

      By

      Markets & Stocks
      US Cannabis Companies Could Finally Get Access to NASDAQ and Financial Services Under New Bill

      By